Preexposure prophylaxis for hiv prevention: What we know and what we still need to know for implementation

Topics in Antiviral Medicine

Volumn 23, Issue 2, 2015, Pages 85-90

  Landovitz, Raphael J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Emtricitabine; HIV; Preexposure prophylaxis; PrEP; PrEP uptake; Resistance; Risk compensation; Tenofovir

Indexed keywords

CABOTEGRAVIR; EMTRICITABINE; RILPIVIRINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; BONE DENSITY; BONE DISEASE; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICATION COMPLIANCE; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCALE UP; SYPHILIS; VIRUS RESISTANCE; DISEASE TRANSMISSION; HIGH RISK BEHAVIOR; HIV INFECTIONS; PRE-EXPOSURE PROPHYLAXIS; PREVENTION AND CONTROL; PROCEDURES;

ANTI-RETROVIRAL AGENTS; DISEASE TRANSMISSION, INFECTIOUS; EMTRICITABINE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; PRE-EXPOSURE PROPHYLAXIS; RISK-TAKING; TENOFOVIR;

EID: 84948748021     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Joint United Nations Programme on HIV/ AIDS (UNAIDS). The gap report, http:// www.unaids.org/sites/default/files/me-dia_asset/UN AIDS_Gap_report_en.pdf. Accessed on May 4, 2015.
2. US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Accessed on April 27, 2015.
3. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoSMed. 2008;5(2):e28.
4. Castillo-Mancilla JR, Meditz A, Wilson C, et al. Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals. J/la/uir Immune Defic Syndr. 2015;68(5):495-501.
5. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci TranslMed. 2011;3(112):112re4.
6. Garcia-Lerma JG, Cong M, Mitchell J, et al. Intermittent prophylaxis with oral Tru-vada protects macaques from rectal SHIV infection. Sci TranslMed. 2010;2(14):l-8.
7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl JMed. 2010;363(27):2587-2599.
8. Grant RM, Lama J, Glidden D, iPrEx Study Team. Pre-exposure chemprophylaxis for prevention of HIV among trans-women and MSM: iPrEx Study [Abstract 92], 18th Conference on Retroviruses and Opportunistic Infections (CROI). February 27-March 3, 2011; Boston, Massachusetts.
9. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
10. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5): 423-434.
11. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. NEnglJMed. 2012;367(5):399-410.
12. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. NEnglJMed. 2015;372(6): 509-518.
13. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151-l25.
14. Cottrell ML, Yang KH, Prince HMA, et al. Predicting effective truvada® PrEP dosing strategies with a novel PK-PD model incorporating tissue active metabolites and endogenous nucleotides (EN). AIDS Res Hum Retroviruses. 2014;30(S1):A60.
15. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.] Acquir Immune Defic Syndr. 2014;66(3): 340-348.
16. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One. 2007; 2(9):e875.
17. Stolte IG, Dukers NH, Geskus RB, Coutinho RA, de Wit JB. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS. 2004;18(2):303-309.
18. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657-666.
19. Bartholow BN, Buchbinder S, Celum C, et al. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39(1):90-101.
20. Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral preexposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13(12):1021-1028.
21. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA. 2010; 107(27): 12381-12386.
22. van de Vijver DA, Nichols BE, Abbas UL, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27(18):2943-2951.
23. Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014;210(8):1217-1227.
24. Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis. 2015;[Epub ahead of print].
25. Grant RM, Liegler T, Defechereux P, et al. Drug resistance and plasma viral RNA level after ineffective use of oral preexposure prophylaxis in women. AIDS. 2015;29(3):331-337
26. Seifert SM, Glidden DV, Meditz AL, et al. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis. 2015;60(5):804-810.
27. Amico KR, Mansoor LE, Corneli A, Torjesen K, Van Der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17(6):2143-2155.
28. Centers for Disease Control and Prevention (CDC). Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014: a clinical practice guideline, http://www.cdc.gov/hiv/pdf/ guidelines/PrEPguidelines2014.pdf. Accessed on May 6, 2015.
29. Buchbinder SP, Glidden DV, Liu AY, et al. HIV pre-exposure prophylaxis in men who have sex with men and transgen-der women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014;14(6):468-475.
30. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820-829.
31. Cohen S, Vittinghoff E, Anderson P, et al. Implementation of PrEP in STD and community health clinics: high uptake and drug concentrations among MSM in the Demo Project [Abstract 377]. 9th International Conference on HIV Treatment and Prevention Adherence. June 8-10, 2014; Miami, Florida.
32. Cohen SE, Vittinghoff E, Bacon O, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP Demonstration Project. J Acquir Immune Defic Syndr. 2015;68(4): 439-448.
33. Grant RM, Liu A, Hecht J et al. Scale-up of preexposure prophylaxis in San Francisco to impact HIV incidence [Abstract 25]. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). February 23-26, 2015; Seattle, Washington.
34. Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18(9):1712-1721.
35. World Health Organization. Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and trans-gender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. http://www.who.int/hiv/pub/guid-ance:prep/en/. Accessed on May 29, 2015.
36. AIDS Vaccine Advocacy Coalition (AVAC). AVAC report 2013: research and reality. http://www.avac.org/sites/default/files/resource-files/AVAC%20Report%202013_ O.pdf. Accessed on June 18, 2015.